Explore the latest news in the pharma industry, including giants like Johnson & Johnson, Pfizer, and Bristol Myers Squibb’s stance on the Inflation Reduction Act, AstraZeneca’s promising drug trials, ICER’s scrutiny of FDA’s approval process, Novo Nordisk’s market capture, and more. Discover in-depth reporting on acquisitions, partnerships, and strategic plans in the healthcare sector.

Explore the latest updates in the biotech industry: Moderna’s Q1 updates with Metagenomi, Novartis’s billion-dollar acquisition of Mariana Oncology, FDA’s request for more data on Dupixent’s COPD treatment, and Bristol Myers’ latest preclinical cancer drug developments. Also, discover funding news from Context Therapeutics and Blueprint Medicines, as well as upcoming decisions affecting Sarepta and Dupixent.

Discover the latest healthcare market news, including UnitedHealth’s interrogation over a cyberattack, Pfizer’s Q1 update and cost-cutting measures, Boehringer Ingelheim’s competition against Humira, legal issues for J&J and Bristol Myers Squibb, controversy over GSK’s inhaler pricing, and J&J’s potential $6.5 billion talc lawsuit settlement plan.

GSK advances timetable for multiple myeloma treatment submission following successful trials. Pfizer modifies pipeline, discontinuing developments on some therapies while advancing others. GSK’s Q1 success due to vaccine portfolio leads to uplifted growth forecast. New data dashboard IRIS introduced by Real Chemistry, integrating diverse clinical trial and market factors. Eli Lilly cancels the trial for key therapies.

Eli Lilly faces supply constraints for its high-demand weight loss and diabetes products, despite boosting sales guidance by $2B. The FTC warns against ‘junk’ patents, while UnitedHealth’s CEO prepares to discuss cybersecurity responses. Additionally, Real Chemistry launches an all-in-one data dashboard and the FDA plans a committee reform with public input.

Eli Lilly ends several high-profile trials including Verzenio and Jardiance, but increases R&D spending by 27%. Meanwhile, Harmony Biosciences purchases Epygenix Therapeutics, enhancing its focus on rare neurological conditions. Start-ups Enlaza Therapeutics and Qlaris Bio secure substantial funding, while Pfizer’s Tivdak gains FDA approval for cervical cancer treatment.

The FDA is overseeing lab-based tests to ensure patient safety, eliciting concerns from lab groups. Merck reveals data supporting its 21-valent pneumonia vaccine, V116’s benefits over Pfizer’s Prevnar 20. Pharma’s reputation sees a dip according to PatientView survey, while Novo Nordisk’s weekly insulin application faces FDA scrutiny. Sanofi promotes Dupixent, and WuXi AppTec pledges to protect clients’ IP rights.

Explore the latest advancements in the biotech industry, including FDA authorization for Prime Medicine’s gene editing clinical trial, Deciphera Pharmaceuticals’ buyout by Ono Pharmaceutical, Bristol Myers’ investment in Repertoire Immune Medicines, and Phase 3 victories for AstraZeneca and Daiichi Sankyo. Also, learn about WuXi Biologics’ attempts to regain client trust and recent developments from 4P-Pharma and Oncotelic Therapeutics.

Explore key developments in the pharmaceutical industry as Senator Bernie Sanders pushes for global access to WHO’s treatments, Evernorth attempts to combat brand-name drug dominance with a cheaper biosimilar, and the FDA approves an updated label for Gilead’s HIV drug. Plus, AbbVie exceeds Q1 expectations despite unclear Humira guidance.

Rising AI biotech firms Generate:Biomedicines and Xaira Therapeutics are making waves with large funding and all-star teams. Meanwhile, AbbVie and Pfizer exceed Q1 expectations with their strategy, drugs and therapies, and companies like UCB and Gilead make strategic changes for growth amidst competition and patent issues.

Explore the latest updates in the pharmaceutical world, including a lawsuit filed by GSK against Pfizer and BioNTech over mRNA patent infringement, efforts by Sage Therapeutics in launching their postpartum depression drug, Esteve’s acquisition of Perrigo’s rare disease pharma business, and Merck KGaA’s massive investment in a new research center.

Exploring strategic changes in the pharmaceutical sector; Bristol Myers Squibb plans $1.5B cost cuts and pipeline streamlining under new CEO, while Merck’s quarterly performance is driven by cancer therapy Keytruda. Other industry news includes Astellas Pharma’s trial adjustments, Cerevance’s $47M investment for Parkinson’s research, and Sanofi’s pivot to become an “immunology powerhouse”.